HawkSoft and RevitPay Partner to Streamline Insurance Payments and Reconciliation with Direct API Integration

RenovoRx has surpassed 100 randomized patients in its Phase III TIGeR-PaC clinical trial, with enrollment expected to complete in H1 2026 and final data in 2027. The trial evaluates the safety and efficacy of intra-arterial gemcitabine delivered via the FDA-cleared RenovoCath device in locally advanced pancreatic cancer. RenovoRx anticipates completing the trial with 114 randomized patients and 86 events.